MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific ...

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...